Related Experiment Video
Updated: Dec 31, 2025
Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
Published on: November 21, 2023
[Immunohistochemical and molecular pathological diagnosis of lung carcinoma]
Britta Janina Wagner1, Reinhard Buettner2
1Institut für Pathologie, Universitätsklinikum und Centrum für Integrierte Onkologie (CIO) Köln, Kerpener Straße 62, 50937, Köln, Deutschland. britta.wagner@uk-koeln.de.
Abstract:
The therapy of lung cancer has revolutionarily changed within the last 15 years. The prognosis of patients has dramatically improved due to targeted therapies, for instance tyrosine kinase inhibitors (TKI). Current recruiting studies are testing new MET-, KRAS-, ROS1-, RET- and NTRK-inhibitors. The first clinical data are promising, emphasizing that it remains a future challenge for pathologists and oncologists to keep an eye on all facets of therapy options. Today, precise lung cancer classification via immunohistochemistry and molecular pathology is crucial for the therapy and prognosis of patients. Further, new biopsy technologies lead to very small tumor tissue samples and cytological samples of high diagnostic quality. Therefore, the complexity of diagnosis needs a strategic procedure to minimize loss of tissue material. This assay gives an overview of efficient and target-orientated diagnostic procedures in consideration of current clinical trials.
Insights
Lung cancer treatment has advanced with targeted therapies like tyrosine kinase inhibitors (TKIs). Efficient diagnostic strategies are crucial for personalized lung cancer classification and patient prognosis, especially with small biopsy samples.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Lung cancer therapy has seen revolutionary changes in the last 15 years.
- Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have significantly improved patient prognosis.
- Ongoing clinical trials are investigating novel inhibitors for MET, KRAS, ROS1, RET, and NTRK.
Purpose of the Study:
- To provide an overview of efficient and target-oriented diagnostic procedures for lung cancer.
- To address the challenges faced by pathologists and oncologists in managing diverse therapy options.
- To guide diagnostic strategies considering the latest clinical trials and advancements in molecular pathology.
Main Methods:
- Review of current diagnostic procedures in lung cancer.
- Integration of immunohistochemistry and molecular pathology for precise classification.
- Consideration of tissue-sparing techniques for small biopsy and cytological samples.
Main Results:
- Precise lung cancer classification is essential for effective therapy and prognosis.
- New biopsy technologies yield high-quality but small tissue samples, necessitating strategic diagnostic approaches.
- Emerging targeted therapies require continuous updates in diagnostic capabilities.
Conclusions:
- Efficient and strategic diagnostic procedures are vital for optimizing lung cancer patient care.
- Pathologists and oncologists must stay abreast of evolving targeted therapies and diagnostic technologies.
- Personalized medicine in lung cancer relies on accurate classification and efficient utilization of limited tissue samples.
